APA (7th ed.) Citation

GL, C., Y, G., Y, Y., Y, S., S, S., X, L., . . . D, J. (2026). A Phase II study of SHR-A1921, a TROP2-targeted antibody-drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma. NPJ precision oncology. https://doi.org/10.1038/s41698-026-01463-5

Chicago Style (17th ed.) Citation

GL, Chen, et al. "A Phase II Study of SHR-A1921, a TROP2-targeted Antibody-drug Conjugate, in Patients with Recurrent or Metastatic Salivary Gland Carcinoma." NPJ Precision Oncology 2026. https://doi.org/10.1038/s41698-026-01463-5.

MLA (9th ed.) Citation

GL, Chen, et al. "A Phase II Study of SHR-A1921, a TROP2-targeted Antibody-drug Conjugate, in Patients with Recurrent or Metastatic Salivary Gland Carcinoma." NPJ Precision Oncology, 2026, https://doi.org/10.1038/s41698-026-01463-5.